Global Product Pipeline
Building the best product pipeline in the industry
A Canadian R&D Leader
GlaxoSmithKline Inc. (GSK) is one of the largest research and development (R&D) organizations in Canada. GSK is one of the top 15 contributors to R&D in Canada, across all industries. Globally, the company spends 6.5 billion every year on R&D.
Clinical Studies
In 2009, GlaxoSmithKline invested close to $38 million in clinical trials across Canada, conducting more than 90 trials and enrolling over 4,000 patients.
- The company supported 44 Collaborative Research Trials (CRTs) in 2009 with physicians across Canada.
- The Clinical Development Group typically works on more than 35 different chemical compounds in clinical development in Canada, varying from phase I to phase IV trials.
Pharmaceutical Development
The company's Pharmaceutical Development Division has developed a number of products including: Zofran® syrup and the fast-disintegrating Zofran® ODT tablets for nausea and vomiting associated with chemotherapy and radiotherapy treatments; and Heptovir® tablets for the treatment of hepatitis B.
The Pathfinders Fund
GlaxoSmithKline's $22 million Pathfinders Fund for Leaders in Canadian Health Science Research was established to help Canada become a world leader in R&D. This initiative encourages health science research and fosters medical innovation in Canadian medical schools.